{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:51:36Z","timestamp":1794009096182,"version":"4.8.0"},"reference-count":200,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/s41572-019-0105-0","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T07:03:20Z","timestamp":1566457400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":820,"title":["Drug-induced liver injury"],"prefix":"10.1038","volume":"5","author":[{"given":"Raul J.","family":"Andrade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar S.","family":"Bj\u00f6rnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd A.","family":"Kullak-Ublick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshad","family":"Devarbhavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Isabel","family":"Lucena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Kaplowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad P.","family":"Aithal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,22]]},"reference":[{"key":"105_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jhep.2015.04.016","volume":"63","author":"M Chen","year":"2015","unstructured":"Chen, M., Suzuki, A., Borlak, J., Andrade, R. J. & Lucena, M. I. Drug-induced liver injury: interactions between drug properties and host factors. J. Hepatol. 63, 503\u2013514 (2015). A concept paper addressing drug properties, patient factors and their interplay in DILI.","journal-title":"J. Hepatol."},{"key":"105_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrd1750","volume":"4","author":"N Kaplowitz","year":"2005","unstructured":"Kaplowitz, N. Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4, 489\u2013499 (2005). Key review highlighting important issues and potential mechanism underlying idiosyncratic DILI.","journal-title":"Nat. Rev. Drug Discov."},{"key":"105_CR3","doi-asserted-by":"publisher","first-page":"724","DOI":"10.7326\/M15-2211","volume":"164","author":"A Reuben","year":"2016","unstructured":"Reuben, A. et al. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Ann. Intern. Med. 164, 724\u2013732 (2016).","journal-title":"Ann. Intern. Med."},{"key":"105_CR4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/apt.13943","volume":"45","author":"MC Donnelly","year":"2017","unstructured":"Donnelly, M. C. et al. Acute liver failure in Scotland: changes in aetiology and outcomes over time (the\u00a0Scottish Look-Back Study). Aliment. Pharmacol. Ther. 45, 833\u2013843 (2017).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"105_CR5","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/hep.1840220312","volume":"22","author":"HJ Zimmerman","year":"1995","unstructured":"Zimmerman, H. J. & Maddrey, W. C. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 22, 767\u2013773 (1995).","journal-title":"Hepatology"},{"key":"105_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1001\/jama.296.1.87","volume":"296","author":"PB Watkins","year":"2006","unstructured":"Watkins, P. B. et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily. JAMA 296, 87\u201393 (2006).","journal-title":"JAMA"},{"key":"105_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/hep.26208","volume":"58","author":"M Chen","year":"2013","unstructured":"Chen, M., Borlak, J. & Tong, W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 58, 388\u2013396 (2013).","journal-title":"Hepatology"},{"key":"105_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.drudis.2008.11.009","volume":"14","author":"JL Stevens","year":"2009","unstructured":"Stevens, J. L. & Baker, T. K. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov. Today 14, 162\u2013167 (2009).","journal-title":"Drug Discov. Today"},{"key":"105_CR9","doi-asserted-by":"crossref","unstructured":"Avigan, M. I. & Mu\u00f1oz, M. A. Perspectives on the regulatory and clinical science of drug-induced liver injury (DILI). en Methods in Pharmacology and Toxicology (eds. Minjun Chen & Yvonne Will) 367-393 (Humana Press, 2018).","DOI":"10.1007\/978-1-4939-7677-5_18"},{"key":"105_CR10","unstructured":"National Institutes of Health. LiverTox: clinical and research information on drug-induced liver injury. Nih.gov https:\/\/livertox.nih.gov (2017)."},{"key":"105_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1378\/chest.99.2.465","volume":"99","author":"MA Steele","year":"1991","unstructured":"Steele, M. A., Burk, R. F. & DesPrez, R. M. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 99, 465\u2013471 (1991).","journal-title":"Chest"},{"key":"105_CR12","first-page":"246","volume":"106","author":"EV Perdices","year":"2014","unstructured":"Perdices, E. V. et al. Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev. Esp. enfermedades Dig. 106, 246\u2013254 (2014).","journal-title":"Rev. Esp. enfermedades Dig."},{"key":"105_CR13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1053\/j.gastro.2013.02.006","volume":"144","author":"ES Bj\u00f6rnsson","year":"2013","unstructured":"Bj\u00f6rnsson, E. S., Bergmann, O. M., Bj\u00f6rnsson, H. K., Kvaran, R. B. & Olafsson, S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144, 1419\u20131425 (2013). A population-based study of the incidence and causes of DILI, and the first study to show the risk of DILI with the use of individual agents.","journal-title":"Gastroenterology"},{"key":"105_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","volume":"56","author":"E Bj\u00f6rnsson","year":"2012","unstructured":"Bj\u00f6rnsson, E., Jacobsen, E. I. & Kalaitzakis, E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J. Hepatol. 56, 374\u2013380 (2012).","journal-title":"J. Hepatol."},{"key":"105_CR15","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani, N. et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 148, 1340\u20131352 (2015).","journal-title":"Gastroenterology"},{"key":"105_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","volume":"129","author":"RJ Andrade","year":"2005","unstructured":"Andrade, R. J. et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129, 512\u2013521 (2005). The primary large publication from the Spanish Hepatotoxicity Registry, with the first large prospective study of patients with DILI.","journal-title":"Gastroenterology"},{"key":"105_CR17","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/hep.27317","volume":"60","author":"VJ Navarro","year":"2014","unstructured":"Navarro, V. J. et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology 60, 1399\u20131408 (2014).","journal-title":"Hepatology"},{"key":"105_CR18","doi-asserted-by":"publisher","first-page":"021","DOI":"10.1055\/s-0038-1623518","volume":"38","author":"R Andrade","year":"2018","unstructured":"Andrade, R., Medina-Caliz, I., Gonzalez-Jimenez, A., Garcia-Cortes, M. & Lucena, M. I. Hepatic damage by natural remedies. Semin. Liver Dis. 38, 021\u2013040 (2018).","journal-title":"Semin. Liver Dis."},{"key":"105_CR19","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/ajg.2012.138","volume":"107","author":"KT Suk","year":"2012","unstructured":"Suk, K. T. et al. A prospective nationwide study of drug-induced liver injury in Korea. Am. J. Gastroenterol. 107, 1380\u20131387 (2012).","journal-title":"Am. J. Gastroenterol."},{"key":"105_CR20","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","volume":"156","author":"T Shen","year":"2019","unstructured":"Shen, T. et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology 156, 2230\u20132241.e11 (2019).","journal-title":"Gastroenterology"},{"key":"105_CR21","unstructured":"World Health Organization. Traditional medicine strategy. 2014-2023. 76 Disponible en: https:\/\/www.who.int\/medicines\/publications\/traditional\/trm_strategy14_23\/en\/ (Accedido: 30.a enero 2019). (2013)."},{"key":"105_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/hepr.13288","volume":"49","author":"M Aiso","year":"2019","unstructured":"Aiso, M. et al. Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan. Hepatol. Res. 49, 105\u2013110 (2019).","journal-title":"Hepatol. Res."},{"key":"105_CR23","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/MEG.0b013e32835f6889","volume":"25","author":"Y Zhou","year":"2013","unstructured":"Zhou, Y. et al. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. Eur. J. Gastroenterol. Hepatol. 25, 825\u2013829 (2013).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"105_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1478-3231.2007.01461.x","volume":"27","author":"C-T Wai","year":"2007","unstructured":"Wai, C.-T. et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int. 27, 465\u2013474 (2007).","journal-title":"Liver Int."},{"key":"105_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12664-018-0820-6","volume":"37","author":"H Devarbhavi","year":"2018","unstructured":"Devarbhavi, H. Ayurvedic and herbal medicine-induced liver injury: it is time to wake up and take notice. Indian J. Gastroenterol. 37, 5\u20137 (2018).","journal-title":"Indian J. Gastroenterol."},{"key":"105_CR26","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/cld.386","volume":"4","author":"G-Q Wang","year":"2014","unstructured":"Wang, G.-Q., Deng, Y.-Q. & Hou, F.-Q. Overview of drug-induced liver injury in China. Clin. Liver Dis. 4, 26\u201329 (2014).","journal-title":"Clin. Liver Dis."},{"key":"105_CR27","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1038\/ajg.2010.287","volume":"105","author":"H Devarbhavi","year":"2010","unstructured":"Devarbhavi, H. et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis and predictors of mortality. Am. J. Gastroenterol. 105, 2396\u20132404 (2010).","journal-title":"Am. J. Gastroenterol."},{"key":"105_CR28","unstructured":"World Health Organization. Global tuberculosis report 2017. Who.int https:\/\/www.who.int\/tb\/publications\/global_report\/gtbr2017_main_text.pdf (2017)."},{"key":"105_CR29","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/liv.13662","volume":"38","author":"H Devarbhavi","year":"2017","unstructured":"Devarbhavi, H. et al. Drug-induced acute liver failure in children and adults: results of a single-centre study of 128 patients. Liver Int. 38, 1322\u20131329 (2017).","journal-title":"Liver Int."},{"key":"105_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2125.2004.02133.x","volume":"58","author":"FJ de Abajo","year":"2004","unstructured":"de Abajo, F. J., Montero, D., Madurga, M. & Rodriguez, L. A. G. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br. J. Clin. Pharmacol. 58, 71\u201380 (2004).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"105_CR31","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/j.1365-2036.2006.03117.x","volume":"24","author":"MB De Valle","year":"2006","unstructured":"De Valle, M. B., Av Klinteberg, V., Alem, N., Olsson, R. & Bj\u00f6rnsson, E. Drug-induced liver injury in a Swedish university hospital out-patient hepatology clinic. Aliment. Pharmacol. Ther. 24, 1187\u20131195 (2006).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"105_CR32","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1053\/jhep.2002.34857","volume":"36","author":"C Sgro","year":"2002","unstructured":"Sgro, C. et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36, 451\u2013455 (2002).","journal-title":"Hepatology"},{"key":"105_CR33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/hep.20800","volume":"42","author":"E Bj\u00f6rnsson","year":"2005","unstructured":"Bj\u00f6rnsson, E. & Olsson, R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42, 481\u2013489 (2005).","journal-title":"Hepatology"},{"key":"105_CR34","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40264-017-0547-9","volume":"40","author":"M Vega","year":"2017","unstructured":"Vega, M. et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: preliminary findings from gastroenterologist-based surveillance in the population of the state of Delaware. Drug Saf. 40, 783\u2013787 (2017). The first population-based study in the USA.","journal-title":"Drug Saf."},{"key":"105_CR35","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1053\/j.gastro.2015.02.050","volume":"148","author":"DS Goldberg","year":"2015","unstructured":"Goldberg, D. S. et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology 148, 1353\u201361.e3 (2015).","journal-title":"Gastroenterology"},{"key":"105_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cld.778","volume":"13","author":"F Bessone","year":"2019","unstructured":"Bessone, F. et al. When the creation of a consortium provides useful answers: experience of the Latin American DILI Network (LATINDILIN). Clin. Liver Dis. 13, 51\u201357 (2019).","journal-title":"Clin. Liver Dis."},{"key":"105_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/toxics6020024","volume":"6","author":"C Amadi","year":"2018","unstructured":"Amadi, C. & Orisakwe, O. Herb-induced liver injuries in developing nations: an update. Toxics 6, 24 (2018).","journal-title":"Toxics"},{"key":"105_CR38","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.cld.2013.07.002","volume":"17","author":"L Yuan","year":"2013","unstructured":"Yuan, L. & Kaplowitz, N. Mechanisms of drug-induced liver injury. Clin. Liver Dis. 17, 507\u2013518 (2013).","journal-title":"Clin. Liver Dis."},{"key":"105_CR39","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.mam.2012.10.009","volume":"34","author":"B Hagenbuch","year":"2013","unstructured":"Hagenbuch, B. & Stieger, B. The SLCO (former SLC21) superfamily of transporters. Mol. Aspects Med. 34, 396\u2013412 (2013).","journal-title":"Mol. Aspects Med."},{"key":"105_CR40","doi-asserted-by":"crossref","unstructured":"Burckhardt, G. & Burckhardt, B. C. in Drug Transporters. Handbook of Experimental Pharmacology, vol 201 (eds. Fromm, M. & Kim, R.) 29\u2013104 (Springer, 2011).","DOI":"10.1007\/978-3-642-14541-4_2"},{"key":"105_CR41","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1053\/gast.2001.21176","volume":"120","author":"GA Kullak-Ublick","year":"2001","unstructured":"Kullak-Ublick, G. A. et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120, 525\u2013533 (2001).","journal-title":"Gastroenterology"},{"key":"105_CR42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1080\/17425255.2017.1253679","volume":"13","author":"D Kovacsics","year":"2017","unstructured":"Kovacsics, D., Patik, I. & \u00d6zvegy-Laczka, C. The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions. Expert Opin. Drug Metab. Toxicol. 13, 409\u2013424 (2017).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"105_CR43","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1124\/jpet.104.068536","volume":"311","author":"Y Shitara","year":"2004","unstructured":"Shitara, Y., Hirano, M., Sato, H. & Sugiyama, Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2\/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311, 228\u2013236 (2004).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"105_CR44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1515\/dmdi-2014-0014","volume":"29","author":"V Khurana","year":"2014","unstructured":"Khurana, V., Minocha, M., Pal, D. & Mitra, A. K. Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors. Drug Metabol. Drug Interact. 29, 249\u2013259 (2014).","journal-title":"Drug Metabol. Drug Interact."},{"key":"105_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1124\/dmd.117.076554","volume":"46","author":"WEA Ellawatty","year":"2018","unstructured":"Ellawatty, W. E. A. et al. Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib. Drug Metab. Dispos. 46, 33\u201340 (2018).","journal-title":"Drug Metab. Dispos."},{"key":"105_CR46","unstructured":"Food and Drug Administration. Guidance document. In vitro metabolism- and transporter-mediated drug-drug interaction studies guidance for industry. Fda.gov https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/vitro-metabolism-and-transporter-mediated-drug-drug-interaction-studies-guidance-industry (2017)."},{"key":"105_CR47","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrd3408","volume":"10","author":"BK Park","year":"2011","unstructured":"Park, B. K. et al. Managing the challenge of chemically reactive metabolites in drug development. Nat. Rev. Drug Discov. 10, 292\u2013306 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"105_CR48","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/17425255.2017.1341489","volume":"13","author":"RJ Weaver","year":"2017","unstructured":"Weaver, R. J. et al. Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury. Expert Opin. Drug Metab. Toxicol. 13, 767\u2013782 (2017).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"105_CR49","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","volume":"132","author":"AK Daly","year":"2007","unstructured":"Daly, A. K. et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132, 272\u2013281 (2007). Candidate gene study highlighting the role of SNPs in genes involved in drug metabolism and excretion.","journal-title":"Gastroenterology"},{"key":"105_CR50","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1124\/dmd.107.019018","volume":"36","author":"Y Li","year":"2008","unstructured":"Li, Y. et al. In vitro metabolic activation of lumiracoxib in rat and human liver preparations. Drug Metab. Dispos. 36, 469\u2013473 (2008).","journal-title":"Drug Metab. Dispos."},{"key":"105_CR51","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1124\/dmd.32.6.639","volume":"32","author":"K He","year":"2004","unstructured":"He, K. et al. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab. Dispos. 32, 639\u2013646 (2004).","journal-title":"Drug Metab. Dispos."},{"key":"105_CR52","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","volume":"66","author":"GA Kullak-Ublick","year":"2017","unstructured":"Kullak-Ublick, G. A. et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 66, 1154\u20131164 (2017). A state-of-the-art review highlighting recent advances in DILI diagnosis.","journal-title":"Gut"},{"key":"105_CR53","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0016-5085(00)70224-1","volume":"118","author":"B Stieger","year":"2000","unstructured":"Stieger, B., Fattinger, K., Madon, J., Kullak-Ublick, G. A. & Meier, P. J. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (BSEP) of rat liver. Gastroenterology 118, 422\u2013430 (2000).","journal-title":"Gastroenterology"},{"key":"105_CR54","first-page":"471","volume":"19","author":"S Kr\u00e4henb\u00fchl","year":"1994","unstructured":"Kr\u00e4henb\u00fchl, S., Talos, C., Fischer, S. & Reichen, J. Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria. Hepatology 19, 471\u2013479 (1994).","journal-title":"Hepatology"},{"key":"105_CR55","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nrgastro.2011.22","volume":"8","author":"S Tujios","year":"2011","unstructured":"Tujios, S. & Fontana, R. J. Mechanisms of drug-induced liver injury: from bedside to bench. Nat. Rev. Gastroenterol. Hepatol. 8, 202\u2013211 (2011).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"105_CR56","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1067\/mcp.2001.114667","volume":"69","author":"K Fattinger","year":"2001","unstructured":"Fattinger, K. et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69, 223\u2013231 (2001).","journal-title":"Clin. Pharmacol. Ther."},{"key":"105_CR57","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/toxsci\/kfq269","volume":"118","author":"RE Morgan","year":"2010","unstructured":"Morgan, R. E. et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol. Sci. 118, 485\u2013500 (2010).","journal-title":"Toxicol. Sci."},{"key":"105_CR58","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1124\/dmd.111.040758","volume":"40","author":"S Dawson","year":"2012","unstructured":"Dawson, S., Stahl, S., Paul, N., Barber, J. & Kenna, J. G. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab. Dispos. 40, 130\u2013138 (2012).","journal-title":"Drug Metab. Dispos."},{"key":"105_CR59","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1124\/mol.59.3.627","volume":"59","author":"C Funk","year":"2001","unstructured":"Funk, C., Ponelle, C., Scheuermann, G. & Pantze, M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59, 627\u2013635 (2001).","journal-title":"Mol. Pharmacol."},{"key":"105_CR60","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/hep.27206","volume":"60","author":"MD Aleo","year":"2014","unstructured":"Aleo, M. D. et al. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 60, 1015\u20131022 (2014).","journal-title":"Hepatology"},{"key":"105_CR61","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-3-642-14541-4_8","volume":"201","author":"D Keppler","year":"2011","unstructured":"Keppler, D. Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb. Exp. Pharmacol. 201, 299\u2013323 (2011).","journal-title":"Handb. Exp. Pharmacol."},{"key":"105_CR62","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/01.fpc.0000236337.41799.b3","volume":"17","author":"JH Choi","year":"2007","unstructured":"Choi, J. H. et al. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet. Genomics 17, 403\u2013415 (2007).","journal-title":"Pharmacogenet. Genomics"},{"key":"105_CR63","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1111\/liv.12193","volume":"33","author":"E Ulzurrun","year":"2013","unstructured":"Ulzurrun, E. et al. Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury. Liver Int. 33, 1378\u20131385 (2013).","journal-title":"Liver Int."},{"key":"105_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-964","volume":"14","author":"Y Miura","year":"2014","unstructured":"Miura, Y. et al. Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype. BMC Cancer 14, 964 (2014).","journal-title":"BMC Cancer"},{"key":"105_CR65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/01.fpc.0000230418.28091.76","volume":"17","author":"C Lang","year":"2007","unstructured":"Lang, C. et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet. Genomics 17, 47\u201360 (2007).","journal-title":"Pharmacogenet. Genomics"},{"key":"105_CR66","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1124\/mol.110.067256","volume":"79","author":"T Yoshikado","year":"2011","unstructured":"Yoshikado, T. et al. Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3\/ABCB4. Mol. Pharmacol. 79, 241\u2013250 (2011).","journal-title":"Mol. Pharmacol."},{"key":"105_CR67","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/hep.28486","volume":"63","author":"S Win","year":"2016","unstructured":"Win, S., Than, T. A., Min, R. W. M., Aghajan, M. & Kaplowitz, N. c-Jun N-terminal kinase mediates mouse liver injury through a novel Sab (SH3BP5)-dependent pathway leading to inactivation of intramitochondrial Src. Hepatology 63, 1987\u20132003 (2016).","journal-title":"Hepatology"},{"key":"105_CR68","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.3390\/ijms18051018","volume":"18","author":"A Iorga","year":"2017","unstructured":"Iorga, A., Dara, L. & Kaplowitz, N. Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis. Int. J. Mol. Sci. 18, 1018 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"105_CR69","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1124\/jpet.116.237578","volume":"360","author":"RA Roth","year":"2017","unstructured":"Roth, R. A., Maiuri, A. R. & Ganey, P. E. Idiosyncratic drug-induced liver injury: is drug-cytokine interaction the linchpin? J. Pharmacol. Exp. Ther. 360, 461\u2013470 (2017).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"105_CR70","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1478-3231.2011.02501.x","volume":"32","author":"H Jaeschke","year":"2012","unstructured":"Jaeschke, H., Williams, C. D., Ramachandran, A. & Bajt, M. L. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int. 32, 8\u201320 (2012).","journal-title":"Liver Int."},{"key":"105_CR71","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/hep.22556","volume":"48","author":"H Jaeschke","year":"2008","unstructured":"Jaeschke, H. Innate immunity and acetaminophen-induced liver injury: why so many controversies? Hepatology 48, 699\u2013701 (2008).","journal-title":"Hepatology"},{"key":"105_CR72","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1002\/hep.27939","volume":"62","author":"L Dara","year":"2015","unstructured":"Dara, L. et al. Receptor interacting protein kinase 1 mediates murine acetaminophen toxicity independent of the necrosome and not through necroptosis. Hepatology 62, 1847\u20131857 (2015).","journal-title":"Hepatology"},{"key":"105_CR73","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1053\/j.gastro.2014.07.018","volume":"147","author":"T Luedde","year":"2014","unstructured":"Luedde, T., Kaplowitz, N. & Schwabe, R. F. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 147, 765\u2013783.e4 (2014).","journal-title":"Gastroenterology"},{"key":"105_CR74","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/hep.29327","volume":"67","author":"LY Yip","year":"2018","unstructured":"Yip, L. Y. et al. The liver-gut microbiota axis modulates hepatotoxicity of tacrine in the rat. Hepatology 67, 282\u2013295 (2018).","journal-title":"Hepatology"},{"key":"105_CR75","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jhep.2018.02.024","volume":"69","author":"S Gong","year":"2018","unstructured":"Gong, S. et al. Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice. J. Hepatol. 69, 51\u201359 (2018).","journal-title":"J. Hepatol."},{"key":"105_CR76","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/hep.26077","volume":"57","author":"MM Monshi","year":"2013","unstructured":"Monshi, M. M. et al. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 57, 727\u2013739 (2013).","journal-title":"Hepatology"},{"key":"105_CR77","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1517\/17425255.2015.992414","volume":"11","author":"JI Grove","year":"2015","unstructured":"Grove, J. I. & Aithal, G. P. Human leukocyte antigen genetic risk factors of drug-induced liver toxicology. Expert Opin. Drug Metab. Toxicol. 11, 395\u2013409 (2015).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"105_CR78","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/hep.26295","volume":"58","author":"N Kaplowitz","year":"2013","unstructured":"Kaplowitz, N. Avoiding idiosyncratic DILI: two is better than one. Hepatology 58, 15\u201317 (2013).","journal-title":"Hepatology"},{"key":"105_CR79","doi-asserted-by":"crossref","unstructured":"Light, D. S., Aleo, M. D. & Kenna, J. G. in Drug-Induced Liver Toxicity. Methods in Pharmacology and Toxicology (eds Chen, M. & Will, Y.) 345\u2013364 (Humana Press, 2018).","DOI":"10.1007\/978-1-4939-7677-5_17"},{"key":"105_CR80","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/cpt.1222","volume":"104","author":"JG Kenna","year":"2018","unstructured":"Kenna, J. G. et al. Can bile salt export pump inhibition testing in drug discovery and development reduce liver injury risk? an international transporter consortium perspective. Clin. Pharmacol. Ther. 104, 916\u2013932 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"105_CR81","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/hep.27824","volume":"62","author":"J Uetrecht","year":"2015","unstructured":"Uetrecht, J. & Kaplowitz, N. Inhibition of immune tolerance unmasks drug-induced allergic hepatitis. Hepatology 62, 346\u2013348 (2015).","journal-title":"Hepatology"},{"key":"105_CR82","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/hep.23720","volume":"52","author":"S Russmann","year":"2010","unstructured":"Russmann, S., Jetter, A. & Kullak-Ublick, G. A. Pharmacogenetics of drug-induced liver injury. Hepatology 52, 748\u2013761 (2010).","journal-title":"Hepatology"},{"key":"105_CR83","unstructured":"Institute of Medicine. Exploring the Biological Contributions to Human Health: Does Sex Matter? (National Academies Press, 2001)."},{"key":"105_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122786","volume":"10","author":"M Mennecozzi","year":"2015","unstructured":"Mennecozzi, M., Landesmann, B., Palosaari, T., Harris, G. & Whelan, M. Sex differences in liver toxicity\u2014do female and male human primary hepatocytes react differently to toxicants in vitro? PLoS One 10, e0122786 (2015).","journal-title":"PLoS One"},{"key":"105_CR85","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.taap.2014.05.010","volume":"279","author":"Y Xie","year":"2014","unstructured":"Xie, Y. et al. Mechanisms of acetaminophen-induced cell death in primary human hepatocytes. Toxicol. Appl. Pharmacol. 279, 266\u2013274 (2014).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"105_CR86","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/toxsci\/kfj192","volume":"92","author":"G Dai","year":"2006","unstructured":"Dai, G., He, L., Chou, N. & Wan, Y.-J. Y. Acetaminophen metabolism does not contribute to gender difference in its hepatotoxicity in mouse. Toxicol. Sci. 92, 33\u201341 (2006).","journal-title":"Toxicol. Sci."},{"key":"105_CR87","first-page":"78","volume":"7","author":"Y Sheng","year":"2013","unstructured":"Sheng, Y., Liang, Q., Deng, Z., Ji, L. & Wang, Z. Acetaminophen induced gender-dependent liver injury and the involvement of GCL and GPx. Drug Discov. Ther. 7, 78\u201383 (2013).","journal-title":"Drug Discov. Ther."},{"key":"105_CR88","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.taap.2014.09.002","volume":"281","author":"K Du","year":"2014","unstructured":"Du, K., Williams, C. D., McGill, M. R. & Jaeschke, H. Lower susceptibility of female mice to acetaminophen hepatotoxicity: role of mitochondrial glutathione, oxidant stress and c-jun N-terminal kinase. Toxicol. Appl. Pharmacol. 281, 58\u201366 (2014).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"105_CR89","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0091-3057(90)90057-O","volume":"37","author":"D Leibman","year":"1990","unstructured":"Leibman, D., Smolen, A. & Smolen, T. N. Strain, sex and developmental profiles of cocaine metabolizing enzymes in mice. Pharmacol. Biochem. Behav. 37, 161\u2013165 (1990).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"105_CR90","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.toxlet.2004.08.008","volume":"155","author":"T Visalli","year":"2005","unstructured":"Visalli, T., Turkall, R. & Abdel-Rahman, M. S. Gender differences in cocaine pharmacokinetics in CF-1 mice. Toxicol. Lett. 155, 35\u201340 (2005).","journal-title":"Toxicol. Lett."},{"key":"105_CR91","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1002\/hep.21425","volume":"44","author":"Q You","year":"2006","unstructured":"You, Q., Cheng, L., Reilly, T. P., Wegmann, D. & Ju, C. Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology 44, 1421\u20131431 (2006).","journal-title":"Hepatology"},{"key":"105_CR92","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/toxsci\/kfr005","volume":"120","author":"CM Dugan","year":"2011","unstructured":"Dugan, C. M., Fullerton, A. M., Roth, R. A. & Ganey, P. E. Natural killer cells mediate severe liver injury in a murine model of halothane hepatitis. Toxicol. Sci. 120, 507\u2013518 (2011).","journal-title":"Toxicol. Sci."},{"key":"105_CR93","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/toxsci\/kfr326","volume":"126","author":"Y Toyoda","year":"2012","unstructured":"Toyoda, Y. et al. Mechanism of exacerbative effect of progesterone on drug-induced liver injury. Toxicol. Sci. 126, 16\u201327 (2012).","journal-title":"Toxicol. Sci."},{"key":"105_CR94","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.toxlet.2011.03.031","volume":"204","author":"Y Toyoda","year":"2011","unstructured":"Toyoda, Y. et al. Estradiol and progesterone modulate halothane-induced liver injury in mice. Toxicol. Lett. 204, 17\u201324 (2011).","journal-title":"Toxicol. Lett."},{"key":"105_CR95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061186","volume":"8","author":"J Cho","year":"2013","unstructured":"Cho, J. et al. Sex bias in experimental immune-mediated, drug-induced liver injury in BALB\/c mice: suggested roles for Tregs, estrogen, and IL-6. PLoS One 8, e61186 (2013).","journal-title":"PLoS One"},{"key":"105_CR96","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.yrtph.2018.01.018","volume":"94","author":"N George","year":"2018","unstructured":"George, N., Chen, M., Yuen, N., Hunt, C. M. & Suzuki, A. Interplay of gender, age and drug properties on reporting frequency of drug-induced liver injury. Regul. Toxicol. Pharmacol. 94, 101\u2013107 (2018).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"105_CR97","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.yrtph.2014.09.007","volume":"70","author":"CM Hunt","year":"2014","unstructured":"Hunt, C. M., Yuen, N. A., Stirnadel-Farrant, H. A. & Suzuki, A. Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database. Regul. Toxicol. Pharmacol. 70, 519\u2013526 (2014).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"105_CR98","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1002\/hep.22895","volume":"49","author":"MI Lucena","year":"2009","unstructured":"Lucena, M. I. et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 49, 2001\u20132009 (2009).","journal-title":"Hepatology"},{"key":"105_CR99","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1111\/liv.13380","volume":"37","author":"A Suzuki","year":"2017","unstructured":"Suzuki, A. et al. Associations of gender and a proxy of female menopausal status with histological features of drug-induced liver injury. Liver Int. 37, 1723\u20131730 (2017).","journal-title":"Liver Int."},{"key":"105_CR100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/liv.13952","volume":"39","author":"A Gonzalez-Jimenez","year":"2019","unstructured":"Gonzalez-Jimenez, A. et al. The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury. Liver Int. 39, 401\u2013410 (2019).","journal-title":"Liver Int."},{"key":"105_CR101","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3390\/ijms17050714","volume":"17","author":"A Ortega-Alonso","year":"2016","unstructured":"Ortega-Alonso, A., Stephens, C., Lucena, M. I. & Andrade, R. J. Case characterization, clinical features and risk factors in drug-induced liver injury. Int. J. Mol. Sci. 17, 714 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"105_CR102","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jhep.2018.05.013","volume":"69","author":"K Kaliyaperumal","year":"2018","unstructured":"Kaliyaperumal, K. et al. Pharmacogenomics of drug-induced liver injury (DILI): molecular biology to clinical applications. J. Hepatol. 69, 948\u2013957 (2018). An up-to-date review of genetic susceptibility to DILI in a clinical context.","journal-title":"J Hepatol"},{"key":"105_CR103","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/liv.14004","volume":"39","author":"H Devarbhavi","year":"2019","unstructured":"Devarbhavi, H. & Raj, S. Drug-induced liver injury with skin reactions: drugs and host risk factors, clinical phenotypes and prognosis. Liver Int. 39, 802\u2013811 (2019).","journal-title":"Liver Int."},{"key":"105_CR104","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/hep.24527","volume":"54","author":"H Devarbhavi","year":"2011","unstructured":"Devarbhavi, H., Karanth, D., Prasanna, K. S., Adarsh, C. K. & Patil, M. Drug-induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents. Hepatology 54, 1344\u20131350 (2011).","journal-title":"Hepatology"},{"key":"105_CR105","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.cgh.2017.05.031","volume":"15","author":"H Devarbhavi","year":"2017","unstructured":"Devarbhavi, H., Raj, S., Joseph, T., Singh, R. & Patil, M. Features and treatment of dapsone-induced hepatitis, based on analysis of 44 cases and literature review. Clin. Gastroenterol. Hepatol. 15, 1805\u20131807 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"105_CR106","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","volume":"156","author":"SH Kardaun","year":"2007","unstructured":"Kardaun, S. H. et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br. J. Dermatol. 156, 609\u2013611 (2007).","journal-title":"Br. J. Dermatol."},{"key":"105_CR107","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","volume":"129","author":"S Bastuji-Garin","year":"1993","unstructured":"Bastuji-Garin, S. et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129, 92\u201396 (1993).","journal-title":"Arch. Dermatol."},{"key":"105_CR108","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s10620-011-1611-4","volume":"56","author":"AJ Czaja","year":"2011","unstructured":"Czaja, A. J. Drug-induced autoimmune-like hepatitis. Dig. Dis. Sci. 56, 958\u2013976 (2011).","journal-title":"Dig. Dis. Sci."},{"key":"105_CR109","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/hep.28270","volume":"63","author":"H Devarbhavi","year":"2016","unstructured":"Devarbhavi, H. et al. Drug-induced liver injury associated with Stevens-Johnson syndrome\/toxic epidermal necrolysis: patient characteristics, causes, and outcome in 36 cases. Hepatology 63, 993\u2013999 (2016).","journal-title":"Hepatology"},{"key":"105_CR110","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal, G. P. et al. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther. 89, 806\u2013815 (2011). This paper established international consensus on case definitions and phenotypic charecterization of DILI.","journal-title":"Clin. Pharmacol. Ther."},{"key":"105_CR111","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/clpt.2012.108","volume":"92","author":"JR Senior","year":"2012","unstructured":"Senior, J. R. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury\u2013past, present, and future. Clin. Pharmacol. Ther. 92, 332\u2013339 (2012).","journal-title":"Clin. Pharmacol. Ther."},{"key":"105_CR112","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/liv.12988","volume":"36","author":"L Dara","year":"2016","unstructured":"Dara, L., Liu, Z.-X. & Kaplowitz, N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 36, 158\u2013165 (2016). A description of various factors that contribute to pathogenesis of idiosyncratic DILI, highlighting the participation of genetic susceptibility due to HLA variants and the potential importance of immune tolerance.","journal-title":"Liver Int."},{"key":"105_CR113","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1053\/j.gastro.2008.09.011","volume":"135","author":"N Chalasani","year":"2008","unstructured":"Chalasani, N. et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 135, 1924\u20131934.e4 (2008).","journal-title":"Gastroenterology"},{"key":"105_CR114","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1053\/j.gastro.2011.07.051","volume":"141","author":"TJ Davern","year":"2011","unstructured":"Davern, T. J. et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 141, 1665\u20131672 (2011).","journal-title":"Gastroenterology"},{"key":"105_CR115","first-page":"423A","volume":"66","author":"R Sanjuan-Jimenez","year":"2017","unstructured":"Sanjuan-Jimenez, R. et al. Prevalence of hepatitis E markers in Spanish patients with suspected drug-induced liver injury [abstract]. Hepatology 66, 423A (2017).","journal-title":"Hepatology"},{"key":"105_CR116","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jhep.2018.03.005","volume":"68","author":"HR Dalton","year":"2018","unstructured":"Dalton, H. R. et al. EASL Clinical Practice Guidelines on hepatitis E virus infection. J. Hepatol. 68, 1256\u20131271 (2018).","journal-title":"J. Hepatol."},{"key":"105_CR117","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/hep.24481","volume":"54","author":"A Suzuki","year":"2011","unstructured":"Suzuki, A. et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 54, 931\u2013939 (2011).","journal-title":"Hepatology"},{"key":"105_CR118","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/cei.12558","volume":"180","author":"DM Foureau","year":"2015","unstructured":"Foureau, D. M. et al. Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin. Exp. Immunol. 180, 40\u201351 (2015).","journal-title":"Clin. Exp. Immunol."},{"key":"105_CR119","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.26709","volume":"59","author":"DE Kleiner","year":"2014","unstructured":"Kleiner, D. E. et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 59, 661\u2013670 (2014).","journal-title":"Hepatology"},{"key":"105_CR120","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/hep.28967","volume":"65","author":"HL Bonkovsky","year":"2017","unstructured":"Bonkovsky, H. L. et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology 65, 1267\u20131277 (2017).","journal-title":"Hepatology"},{"key":"105_CR121","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1517\/14740330903397378","volume":"8","author":"RJ Andrade","year":"2009","unstructured":"Andrade, R. J., Robles, M. & Lucena, M. I. Rechallenge in drug-induced liver injury: the attractive hazard. Expert Opin. Drug Saf. 8, 709\u2013714 (2009).","journal-title":"Expert Opin. Drug Saf."},{"key":"105_CR122","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jhep.2011.02.007","volume":"55","author":"M Garc\u00eda-Cort\u00e9s","year":"2011","unstructured":"Garc\u00eda-Cort\u00e9s, M., Stephens, C., Lucena, M. I., Fern\u00e1ndez-Casta\u00f1er, A. & Andrade, R. J. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J. Hepatol. 55, 683\u2013691 (2011). A comprehensive review on the shortcomings of the liver-specific CIOMS\/RUCAM scale.","journal-title":"J. Hepatol."},{"key":"105_CR123","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/j.1365-2036.2008.03655.x","volume":"27","author":"M Garc\u00eda-Cort\u00e9s","year":"2008","unstructured":"Garc\u00eda-Cort\u00e9s, M. et al. Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug-induced liver injury. Aliment. Pharmacol. Ther. 27, 780\u2013789 (2008).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"105_CR124","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","volume":"46","author":"G Danan","year":"1993","unstructured":"Danan, G. & Benichou, C. Causality assessment of adverse reactions to drugs\u2014I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol. 46, 1323\u20131330 (1993).","journal-title":"J. Clin. Epidemiol."},{"key":"105_CR125","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/jhep.2001.20645","volume":"33","author":"M Lucena","year":"2001","unstructured":"Lucena, M., Camargo, R., Andrade, R. J., Perez-Sanchez, C. J. & Sanchez De La Cuesta, F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 33, 123\u2013130 (2001).","journal-title":"Hepatology"},{"key":"105_CR126","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: drug-induced liver injury. J Hepatol. 70, 1222-1261 (2019). A comprehensive review of DILI and recommendations for clinical practice.","DOI":"10.1016\/j.jhep.2019.02.014"},{"key":"105_CR127","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/hep.22442","volume":"48","author":"J Rochon","year":"2008","unstructured":"Rochon, J. et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 48, 1175\u20131183 (2008).","journal-title":"Hepatology"},{"key":"105_CR128","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/hep.28813","volume":"65","author":"VJ Navarro","year":"2017","unstructured":"Navarro, V. J. et al. Liver injury from herbal and dietary supplements. Hepatology 65, 363\u2013373 (2017).","journal-title":"Hepatology"},{"key":"105_CR129","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/liv.13746","volume":"38","author":"DL Suzman","year":"2018","unstructured":"Suzman, D. L., Pelosof, L., Rosenberg, A. & Avigan, M. I. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 38, 976\u2013987 (2018).","journal-title":"Liver Int."},{"key":"105_CR130","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/hep.23577","volume":"51","author":"DC Rockey","year":"2010","unstructured":"Rockey, D. C. et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 51, 2117\u20132126 (2010).","journal-title":"Hepatology"},{"key":"105_CR131","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/ijms17020201","volume":"17","author":"PH Hayashi","year":"2016","unstructured":"Hayashi, P. H. Drug-induced liver injury network causality assessment: criteria and experience in the United States. Int. J. Mol. Sci. 17, 201 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"105_CR132","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1111\/liv.12540","volume":"35","author":"PH Hayashi","year":"2015","unstructured":"Hayashi, P. H. et al. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int. 35, 1623\u20131632 (2015).","journal-title":"Liver Int."},{"key":"105_CR133","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S1386-6346(03)00232-8","volume":"27","author":"H Takikawa","year":"2003","unstructured":"Takikawa, H. et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol. Res. 27, 192\u2013195 (2003).","journal-title":"Hepatol. Res."},{"key":"105_CR134","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/1547691X.2016.1254305","volume":"14","author":"J Whritenour","year":"2017","unstructured":"Whritenour, J. et al. Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. J. Immunotoxicol. 14, 31\u201338 (2017).","journal-title":"J. Immunotoxicol."},{"key":"105_CR135","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.cgh.2018.04.049","volume":"16","author":"A Benesic","year":"2018","unstructured":"Benesic, A. et al. Development and validation of a test to identify drugs that cause idiosyncratic drug-induced liver injury. Clin. Gastroenterol. Hepatol. 16, 1488\u20131494.e5 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"105_CR136","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms17010014","volume":"17","author":"G Danan","year":"2015","unstructured":"Danan, G. & Teschke, R. RUCAM in drug and herb induced liver injury: the update. Int. J. Mol. Sci. 17, 14 (2015).","journal-title":"Int. J. Mol. Sci."},{"key":"105_CR137","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/liv.13441","volume":"37","author":"RJ Church","year":"2017","unstructured":"Church, R. J. & Watkins, P. B. The transformation in biomarker detection and management of drug-induced liver injury. Liver Int. 37, 1582\u20131590 (2017).","journal-title":"Liver Int."},{"key":"105_CR138","unstructured":"Food and Drug Administration. FDA letter of support for drug-induced liver injury (DILI) biomarkers. Fda.gov https:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/UCM517355.pdf (2016)."},{"key":"105_CR139","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s13238-012-2036-3","volume":"3","author":"J Hu","year":"2012","unstructured":"Hu, J. et al. MiR-122 in hepatic function and liver diseases. Protein Cell 3, 364\u2013371 (2012).","journal-title":"Protein Cell"},{"key":"105_CR140","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/hep.29802","volume":"69","author":"RJ Church","year":"2019","unstructured":"Church, R. J. et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology 69, 760\u2013763 (2019).","journal-title":"Hepatology"},{"key":"105_CR141","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1053\/j.gastro.2016.07.031","volume":"151","author":"M Rivkin","year":"2016","unstructured":"Rivkin, M. et al. Inflammation-induced expression and secretion of microRNA 122 leads to reduced blood levels of kidney-derived erythropoietin and anemia. Gastroenterology 151, 999\u20131010.e3 (2016).","journal-title":"Gastroenterology"},{"key":"105_CR142","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1053\/j.gastro.2017.08.013","volume":"153","author":"C Chai","year":"2017","unstructured":"Chai, C. et al. Metabolic circuit involving free fatty acids, microRNA 122, and triglyceride synthesis in liver and muscle tissues. Gastroenterology 153, 1404\u20131415 (2017).","journal-title":"Gastroenterology"},{"key":"105_CR143","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1002\/hep.29863","volume":"67","author":"RJ Church","year":"2018","unstructured":"Church, R. J. & Watkins, P. B. Reply. Hepatology 67, 2481\u20132482 (2018).","journal-title":"Hepatology"},{"key":"105_CR144","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0009-8981(88)90356-7","volume":"173","author":"ES Schmidt","year":"1988","unstructured":"Schmidt, E. S. & Schmidt, F. W. Glutamate dehydrogenase: biochemical and clinical aspects of an interesting enzyme. Clin. Chim. Acta. 173, 43\u201355 (1988).","journal-title":"Clin. Chim. Acta."},{"key":"105_CR145","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/liv.13312","volume":"37","author":"MW Russo","year":"2017","unstructured":"Russo, M. W. et al. Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. Liver Int. 37, 757\u2013764 (2017).","journal-title":"Liver Int."},{"key":"105_CR146","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081974","volume":"8","author":"NM Steuerwald","year":"2013","unstructured":"Steuerwald, N. M. et al. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One 8, e81974 (2013).","journal-title":"PLoS One"},{"key":"105_CR147","unstructured":"Zimmerman, H. J. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. (Lippincott Williams and Wilkins, 1999)."},{"key":"105_CR148","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pds.1211","volume":"15","author":"R Temple","year":"2006","unstructured":"Temple, R. Hy\u2019s law: predicting serious hepatotoxicity. Pharmacoepidemiol. Drug Saf. 15, 241\u2013243 (2006).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"Suppl 1","key":"105_CR149","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1007\/s40264-014-0182-7","volume":"37","author":"JR Senior","year":"2014","unstructured":"Senior, J. R. Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges. Drug Saf. 37 (Suppl 1), S9\u2013S17 (2014). An important paper from the regulatory perspective of the risk of DILI with new compounds.","journal-title":"Drug Saf."},{"key":"105_CR150","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","volume":"147","author":"M Robles\u2013Diaz","year":"2014","unstructured":"Robles\u2013Diaz, M. et al. Use of Hy\u2019s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 147, 109\u2013118 (2014).","journal-title":"Gastroenterology"},{"key":"105_CR151","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jhep.2005.12.016","volume":"44","author":"E Bj\u00f6rnsson","year":"2006","unstructured":"Bj\u00f6rnsson, E., Nordlinder, H. & Olsson, R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J. Hepatol. 44, 791\u2013797 (2006).","journal-title":"J. Hepatol."},{"key":"105_CR152","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jhep.2008.03.017","volume":"49","author":"K Pachkoria","year":"2008","unstructured":"Pachkoria, K. et al. Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J. Hepatol. 49, 107\u2013114 (2008).","journal-title":"J. Hepatol."},{"key":"105_CR153","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jhep.2016.05.003","volume":"65","author":"I Medina-Caliz","year":"2016","unstructured":"Medina-Caliz, I. et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J. Hepatol. 65, 532\u2013542 (2016).","journal-title":"J. Hepatol."},{"key":"105_CR154","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/hep.29283","volume":"66","author":"PH Hayashi","year":"2017","unstructured":"Hayashi, P. H. et al. Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology 66, 1275\u20131285 (2017).","journal-title":"Hepatology"},{"key":"105_CR155","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/14740338.2018.1505861","volume":"17","author":"M Garc\u00eda-Cort\u00e9s","year":"2018","unstructured":"Garc\u00eda-Cort\u00e9s, M., Ortega-Alonso, A., Lucena, M. I. & Andrade, R. J. Drug-induced liver injury: a safety review. Expert Opin. Drug Saf. 17, 795\u2013804 (2018).","journal-title":"Expert Opin. Drug Saf."},{"key":"105_CR156","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0034-1375962","volume":"34","author":"A Regev","year":"2014","unstructured":"Regev, A. Drug-induced liver injury and drug development: industry perspective. Semin. Liver Dis. 34, 227\u2013239 (2014).","journal-title":"Semin. Liver Dis."},{"key":"105_CR157","unstructured":"Food and Drug Administration. Guidance document. Drug-induced liver injury: premarketing clinical evaluation. Fda.gov https:\/\/www.fda.gov\/downloads\/Guidances\/UCM174090.pdf (2009). A key guidance document for industry on detecting, assessing and managing liver toxicity in clinical trials."},{"key":"105_CR158","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2017-314924","volume":"67","author":"PN Newsome","year":"2018","unstructured":"Newsome, P. N. et al. Guidelines on the management of abnormal liver blood tests. Gut 67, 6\u201319 (2018).","journal-title":"Gut"},{"key":"105_CR159","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.tox.2007.11.021","volume":"245","author":"J Ozer","year":"2008","unstructured":"Ozer, J., Ratner, M., Shaw, M., Bailey, W. & Schomaker, S. The current state of serum biomarkers of hepatotoxicity. Toxicology 245, 194\u2013205 (2008).","journal-title":"Toxicology"},{"key":"105_CR160","first-page":"149","volume":"23","author":"CM Hunt","year":"2009","unstructured":"Hunt, C. M., Forster, J. K., Papay, J. I. & Stirnadel, H. A. Evidence-based liver chemistry monitoring in drug development. Pharmaceut. Med. 23, 149\u2013158 (2009). A retrospective analysis of time-to-onset, incidence, phenotype and severity of liver injury in clinical trials with recommendation on monitoring intervals by development stage.","journal-title":"Pharmaceut. Med."},{"key":"105_CR161","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1056\/NEJMra021844","volume":"349","author":"WM Lee","year":"2003","unstructured":"Lee, W. M. Drug-induced hepatotoxicity. N. Engl. J. Med. 349, 474\u2013485 (2003).","journal-title":"N. Engl. J. Med."},{"key":"105_CR162","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jceh.2012.05.002","volume":"2","author":"H Devarbhavi","year":"2012","unstructured":"Devarbhavi, H. An update on drug-induced liver Injury. J. Clin. Exp. Hepatol. 2, 247\u2013259 (2012).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"105_CR163","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/pds.1212","volume":"15","author":"N Kaplowitz","year":"2006","unstructured":"Kaplowitz, N. Rules and laws of drug hepatotoxicity. Pharmacoepidemiol. Drug Saf. 15, 231\u2013233 (2006).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"105_CR164","unstructured":"Guo, T., Senior, J., Gelperin, K. & Food and Drug Administration. How a SAS\/IntrNet tool was created at the FDA for the detection of potential drug-induced liver injury using data with CDISC standard. Lexjansen.com https:\/\/www.lexjansen.com\/wuss\/2009\/cdi\/CDI-Guo.pdf (2008)."},{"key":"105_CR165","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2165\/11586600-000000000-00000","volume":"34","author":"PB Watkins","year":"2011","unstructured":"Watkins, P. B. et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 34, 243\u2013252 (2011).","journal-title":"Drug Saf."},{"key":"105_CR166","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40264-014-0184-5","volume":"37","author":"M Merz","year":"2014","unstructured":"Merz, M., Lee, K. R., Kullak-Ublick, G. A., Brueckner, A. & Watkins, P. B. Methodology to assess clinical liver safety data. Drug Saf. 37, 33\u201345 (2014).","journal-title":"Drug Saf."},{"key":"105_CR167","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0002-9343(02)01529-2","volume":"114","author":"DJ Graham","year":"2003","unstructured":"Graham, D. J., Green, L., Senior, J. R. & Nourjah, P. Troglitazone-induced liver failure: a case study. Am. J. Med. 114, 299\u2013306 (2003).","journal-title":"Am. J. Med."},{"key":"105_CR168","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1572-0241.2003.07175.x","volume":"98","author":"DJ Graham","year":"2003","unstructured":"Graham, D. J., Drinkard, C. R. & Shatin, D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am. J. Gastroenterol. 98, 175\u2013179 (2003).","journal-title":"Am. J. Gastroenterol."},{"key":"105_CR169","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jama.286.7.831","volume":"286","author":"DJ Graham","year":"2001","unstructured":"Graham, D. J., Drinkard, C. R., Shatin, D., Tsong, Y. & Burgess, M. J. Liver enzyme monitoring in patients treated with troglitazone. JAMA 286, 831\u2013833 (2001).","journal-title":"JAMA"},{"key":"105_CR170","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ajg.2014.131","volume":"109","author":"NP Chalasani","year":"2014","unstructured":"Chalasani, N. P. et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am. J. Gastroenterol. 109, 950\u2013966 (2014). The first guidelines for the diagnosis and management of DILI.","journal-title":"Am. J. Gastroenterol."},{"key":"105_CR171","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov, I. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5, 95 (2017).","journal-title":"J. Immunother. cancer"},{"key":"105_CR172","first-page":"25A","volume":"68","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih, H., Styskel, B., Blechazz, B., Chalasani, N. & Miller, E. Clinically significant hepatotoxicity due to immune checkpoint inhibitors is rare but leads to treatment discontinuations in high proportion. Hepatology 68, 25A (2018).","journal-title":"Hepatology"},{"key":"105_CR173","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin, E. et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J. Hepatol. 68, 1181\u20131190 (2018).","journal-title":"J. Hepatol."},{"key":"105_CR174","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jhep.2018.03.034","volume":"69","author":"M-L Gauci","year":"2018","unstructured":"Gauci, M.-L. et al. Immune-related hepatitis with immunotherapy: are corticosteroids always needed? J. Hepatol. 69, 548\u2013550 (2018).","journal-title":"J. Hepatol."},{"key":"105_CR175","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1053\/j.gastro.2009.06.006","volume":"137","author":"WM Lee","year":"2009","unstructured":"Lee, W. M. et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 137, 856\u2013864 (2009).","journal-title":"Gastroenterology"},{"key":"105_CR176","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/BF03262001","volume":"35","author":"TF Butt","year":"2012","unstructured":"Butt, T. F., Cox, A. R., Oyebode, J. R. & Ferner, R. E. Internet accounts of serious adverse drug reactions: a study of experiences of Stevens-Johnson syndrome and toxic epidermal necrolysis. Drug Saf. 35, 1159\u20131170 (2012).","journal-title":"Drug Saf."},{"key":"105_CR177","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.yebeh.2015.11.009","volume":"54","author":"AB Kowski","year":"2016","unstructured":"Kowski, A. B. et al. Specific adverse effects of antiepileptic drugs\u2013a true-to-life monotherapy study. Epilepsy Behav. 54, 150\u2013157 (2016).","journal-title":"Epilepsy Behav."},{"key":"105_CR178","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware","year":"1992","unstructured":"Ware, J. E. & Sherbourne, C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30, 473\u2013483 (1992).","journal-title":"Med. Care"},{"key":"105_CR179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08870449908407311","volume":"14","author":"R Horne","year":"1999","unstructured":"Horne, R., Weinman, J. & Hankins, M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol. Heal. 14, 1\u201324 (1999).","journal-title":"Psychol. Heal."},{"key":"105_CR180","doi-asserted-by":"publisher","first-page":"9069","DOI":"10.3748\/wjg.v19.i47.9069","volume":"19","author":"JI Suh","year":"2013","unstructured":"Suh, J. I. et al. Anxiety and depression propensities in patients with acute toxic liver injury. World J. Gastroenterol. 19, 9069\u20139076 (2013).","journal-title":"World J. Gastroenterol."},{"key":"105_CR181","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/ajg.2015.283","volume":"110","author":"RJ Fontana","year":"2015","unstructured":"Fontana, R. J. et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am. J. Gastroenterol. 110, 1450\u20131459 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"105_CR182","doi-asserted-by":"publisher","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","volume":"137","author":"G Ostapowicz","year":"2002","unstructured":"Ostapowicz, G. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137, 947\u2013954 (2002).","journal-title":"Ann. Intern. Med."},{"key":"105_CR183","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/lt.23688","volume":"19","author":"AS Rangnekar","year":"2013","unstructured":"Rangnekar, A. S. et al. Quality of life is significantly impaired in long-term survivors of acute liver failure and particularly in acetaminophen-overdose patients. Liver Transpl. 19, 991\u20131000 (2013).","journal-title":"Liver Transpl."},{"key":"105_CR184","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/MAJ.0b013e3181e15da8","volume":"340","author":"FS Rzouq","year":"2010","unstructured":"Rzouq, F. S. et al. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am. J. Med. Sci. 340, 89\u201393 (2010).","journal-title":"Am. J. Med. Sci."},{"key":"105_CR185","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/cts.12629","volume":"12","author":"PB Watkins","year":"2019","unstructured":"Watkins, P. B. The DILI-sim initiative: insights into hepatotoxicity. mechanisms and biomarker interpretation. Clin. Transl. Sci. 12, 122\u2013129 (2019). This is a review of a 15 year public\u2013private partnership that has been using quantitative systems toxicology approaches to understand and predict the likelihood that a new drug candidate will cause DILI. The review focuses on specific advances in mechanistic understanding that have evolved from this consortium.","journal-title":"Clin. Transl. Sci."},{"key":"105_CR186","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1111\/liv.12836","volume":"35","author":"GP Aithal","year":"2015","unstructured":"Aithal, G. P. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int. 35, 1801\u20131808 (2015).","journal-title":"Liver Int."},{"key":"105_CR187","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","volume":"31","author":"F Alvarez","year":"1999","unstructured":"Alvarez, F. et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 31, 929\u2013938 (1999).","journal-title":"J. Hepatol."},{"key":"105_CR188","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/s41588-018-0168-y","volume":"50","author":"K Kowalec","year":"2018","unstructured":"Kowalec, K. et al. Common variation near IRF6 is associated with IFN-\u03b2-induced liver injury in multiple sclerosis. Nat. Genet. 50, 1081\u20131085 (2018).","journal-title":"Nat. Genet."},{"key":"105_CR189","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1053\/j.gastro.2019.01.034","volume":"156","author":"ET Cirulli","year":"2019","unstructured":"Cirulli, E. T. et al. A missense variant in PTPN22 is a risk factor for drug-induced liver injury. Gastroenterology 156, 1707\u20131716.e2 (2019).","journal-title":"Gastroenterology"},{"key":"105_CR190","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/gim.2016.33","volume":"19","author":"M Kozyra","year":"2017","unstructured":"Kozyra, M., Ingelman-Sundberg, M. & Lauschke, V. M. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet. Med. 19, 20\u201329 (2017).","journal-title":"Genet. Med."},{"key":"105_CR191","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/s41588-018-0183-z","volume":"50","author":"AV Khera","year":"2018","unstructured":"Khera, A. V. et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 50, 1219\u20131224 (2018).","journal-title":"Nat. Genet."},{"key":"105_CR192","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/hep.27549","volume":"61","author":"IG Metushi","year":"2015","unstructured":"Metushi, I. G., Hayes, M. A. & Uetrecht, J. Treatment of PD-1(-\/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology 61, 1332\u20131342 (2015).","journal-title":"Hepatology"},{"key":"105_CR193","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2014.03.045","volume":"147","author":"RJ Fontana","year":"2014","unstructured":"Fontana, R. J. et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 147, 96\u2013108 (2014).","journal-title":"Gastroenterology"},{"key":"105_CR194","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/toxsci\/kft087","volume":"134","author":"H Jaeschke","year":"2013","unstructured":"Jaeschke, H. & McGill, M. R. Serum glutamate dehydrogenase\u2014biomarker for liver cell death or mitochondrial dysfunction? Toxicol. Sci. 134, 221\u2013222 (2013).","journal-title":"Toxicol. Sci."},{"key":"105_CR195","doi-asserted-by":"publisher","first-page":"32042","DOI":"10.1016\/j.jhep.2018.04.024","volume":"S0168-8278","author":"B Francis","year":"2018","unstructured":"Francis, B. et al. Temporary removal: reference intervals for putative biomarkers of drug-induced liver injury and liver regeneration in healthy human volunteers. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2018.04.024 (2018).","journal-title":"J. Hepatol."},{"key":"105_CR196","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.yrtph.2015.05.004","volume":"72","author":"A Suzuki","year":"2015","unstructured":"Suzuki, A. et al. Comedications alter drug-induced liver injury reporting frequency: data mining in the WHO VigiBaseTM. Regul. Toxicol. Pharmacol. 72, 481\u2013490 (2015).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"105_CR197","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.cgh.2009.03.034","volume":"7","author":"A Suzuki","year":"2009","unstructured":"Suzuki, A. et al. Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. Clin. Gastroenterol. Hepatol. 7, 882\u2013888 (2009).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"105_CR198","doi-asserted-by":"publisher","first-page":"J187","DOI":"10.1016\/j.jaut.2011.11.012","volume":"38","author":"I Bianchi","year":"2012","unstructured":"Bianchi, I., Lleo, A., Gershwin, M. E. & Invernizzi, P. The X chromosome and immune associated genes. J. Autoimmun. 38, J187\u2013J192 (2012).","journal-title":"J. Autoimmun."},{"key":"105_CR199","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/QAD.0000000000001093","volume":"30","author":"K Gianesin","year":"2016","unstructured":"Gianesin, K. et al. Premature aging and immune senescence in HIV-infected children. AIDS 30, 1363\u20131373 (2016).","journal-title":"AIDS"},{"key":"105_CR200","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1478-3231.2005.01178.x","volume":"26","author":"T Nakajima","year":"2006","unstructured":"Nakajima, T. et al. Premature telomere shortening and impaired regenerative response in hepatocytes of individuals with NAFLD. Liver Int. 26, 23\u201331 (2006).","journal-title":"Liver Int."}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41572-019-0105-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-019-0105-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41572-019-0105-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T07:39:01Z","timestamp":1721633941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41572-019-0105-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,22]]},"references-count":200,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["105"],"URL":"https:\/\/doi.org\/10.1038\/s41572-019-0105-0","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,22]]},"assertion":[{"value":"4 July 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests in this topic.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}